Evaluating Molecular Mutations in AML Patients from Turkey

Certain genetic mutations may play a role in the etiology of acute myeloid leukemia (AML). Therefore, a study aimed to assess the distribution of genetic mutations in AML patients from Turkey. The results appeared in the journal Medicine.

This retrospective analysis consisted of 126 patients diagnosed with AML, who had molecular mutation test results or records in their patient files. Any patients who were not citizens of the Republic of Turkey were excluded from analysis.

The researchers observed that analyses for at least 1 c-kit exon mutation had been carried out on 76 patients, which detected no c-kit mutation among the types of genetic mutations investigated in 100% of those individuals. The results showed that the frequency of FMS-like tyrosine kinase 3-internal tandem duplication mutations was 25%.

“The prevalence of translocation (15;17) was approximately 11% and the prevalence of translocation (8;21) was % 6.25. In addition, we also showed that the frequency of inversion16 was nearly 3.7%,” the researchers wrote of the results. They concluded that “the possibility of c-kit mutation in AML patients from Turkey might actually be low.”